Carl Ross, Managing Director
Waisman Biomanufacturing has in-depth experience in manufacturing a wide range of biotherapeutics for human clinical trials including gene therapeutics, cell therapeutics, vaccines, and recombinant proteins. Waisman has developed platform manufacturing processes and analytical methods to support clinical production of several classes of biotherapeutics including plasmid DNA, Mesenchymal Stromal Cells (MSCs), human Embryonic Stem Cells (hESCs), adenoviral vectors, and lentiviral vectors. In addition, Waisman has supported the development and clinical production of a number of novel types of biotherapeutics from process development through to aseptic fill and finish. For more information, see the Waisman Biomanufacturing facility’s website.